Study type: A prospective, randomized, double-blind, placebo-controlled study on the safety and efficacy of Golden Lite (blood sugar management) and Vita Power supplements for patients with type II Diabetes Mellitus.
Objectives: Test the efficacy and safety of Gluco Low and Vita Power supplements by assessing the following symptoms and physical findings:
- Increased thirst and frequent urination: As excess sugar builds up in your bloodstream, fluid is pulled from your tissues. This may leave you thirsty. As a result, you may drink — and urinate — more than usual.
- Extreme hunger: Without enough insulin to move sugar, your muscles and organs become depleted of energy. This triggers intense hunger which may persist even after eating.
- Weight loss: Despite eating more than usual to relieve constant hunger, weight loss may occur. Without the energy that sugar supplies, muscle tissues and fat stores may simply shrink.
- Fatigue: If cells are deprived of sugar, drowsiness and irritability may occur.
- Blurred vision: If blood sugar level is too high, fluid may be pulled from your tissues including from the lenses of your eyes. This may affect the ability to focus.
- Slow-healing sores or frequent infections: Type II diabetes affects the ability to heal and fight infections. Bladder and vaginal infections can be a particular problem for women. Abdominal pain, bloating, constipation, diarrhea, and mucus with bowel movements can also occur.
- Random blood sugar test: A blood sample will be taken at random times. Regardless of when the last meal occurred, a random blood sugar level of 200 milligrams per deciliter (mg/dL) or higher suggests diabetes.
- Fasting blood sugar test: A blood sample was taken after an overnight fast. A fasting blood sugar level between 70 and 100 mg/dL is normal. A fasting blood sugar level from 100 to 125 mg/dL is considered prediabetic which indicates a high risk of developing diabetes. A fasting blood sugar level of 126 mg/dL or higher on two separate tests is considered a diabetes diagnosis.
- Glycated hemoglobin test: A glycated hemoglobin test, also called a glycosylated hemoglobin test or hemoglobin A1C test measures the average blood sugar level for the two- to three-month period before the test. It is used to determine how well you’re managing your blood sugar.
- Serum creatinine test. This test measures the level of creatinine in the blood. Creatinine is a chemical waste product that’s produced when muscles are used. If kidneys aren’t functioning properly, they aren’t able to remove as much creatinine from the blood.
- Urine microalbumin test. A urine microalbumin test assesses the health of the kidneys by screening for protein leakage in urine. If kidneys become damaged, waste products normally filtered out by the kidneys remain in the blood, and protein (albumin) that should remain in the blood leaks into urine.
- Lipids test. A lipids test measures the level of fats (lipids) in the blood. A rising level of certain blood fats can indicate an increased risk of blood vessel damage. The test measures the level of two such substances that increase your heart disease risk: low-density lipoprotein (LDL), the “bad” cholesterol, and triglycerides. The test also determines your level of high-density lipoprotein (HDL), the “good” cholesterol, which protects against heart disease.
Materials and methods: Sixty subjects underwent randomization and were divided into two groups to receive either the active investigational products Gluco Low and Vita Power or a placebo with a non-active recipient. The duration of the study trial was 90 days. Patients were screened to meet the inclusion and exclusion criteria for the study protocol. Thereafter, three follow-up visits were scheduled at weeks 4, 8, and 12 to ascertain the subjects’ symptoms and physical findings.
Conclusion: One 800mg capsule of Golden Lite taken 4 times per day, and one 800mg capsule of Vita Power taken 2 times per day demonstrated a significant improvement in reducing the symptoms stated above and physical findings at the clinical trial’s conclusion. Moreover, investigators determined that no adverse events from the ingestion of the investigational products occurred.
Study Investigators
Study Coordinator: Jack Haddad, MD, MBA, Orthopedic Surgery, UCSF Medical Center, San Francisco, CA
Charlie Khano, MD, Internal Medicine, Nephrologist, Private Practice, Union City, CA
Judy Weinberg, MD, Internal Medicine, Endocrinologist, University of Pennsylvania School of Medicine, Philadelphia, PA.
Andrew Winstin, MD, Internal Medicine, Endocrinologist, Private Practice, San Francisco, CA
Phillip Shinnick, D.C., Ph.D., The Research Institute of Global Physiology, Behavior, and Treatment, INC., New York, NY
Cindy Maloore, Ph.D., Nutritionist, Private Practice, Santa Clara, CA